Aventis Lovenox patents
Executive Summary
Aventis will not file patent infringement lawsuit against Amphastar to enforce Lovenox patent No. 4,692,435, set to expire in December 2004. Aventis' defense against enoxaparin generics is focused on the re-issuance of another patent (No. 5,389,618) that will expire in February 2012. The company received a 30-month stay of approval based on a suit against Amphastar and Teva on the original '618 patent (1"The Pink Sheet" Aug. 18, 2003, p. 16)...
You may also be interested in...
Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay
Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.